Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IMS data means little when the field is already flooded with competitors. I find it funny how this is always ignored by "investors".
I find it hysterically funny that we all "know" it is going to trade at $1. Basics of supply and demand tell us otherwise. If we all knew that the stock would fill that gap up to the discounted value of today.
Not sure I see that today, but I do see lots of selling pressure.
There may be some truth to that. Extreme confidence to stabilize stock (never happened after cc though) to allow further and further dilution.
I don't think the trading is a signal of the results. I was only implying the tone in which Nasrat used didn't signal confidence in favorable results.
Wow. Only missed by 5 years so far. About as accurate as all the other forecasts as well.
How is Epic's Oxy game changer faring again? Probably going to be outdone by Trimipramine.
Again, not in this most recent call. No dollar amount was stated because of all the additional dilution. Can't get to a buck now without an R/S.
That was my opinion as stated. Saying defined thresholds as stated by CEO is not a fact, but a pure lie.
He said nothing about any dollar threshold. That is a completely made up statement not based on any fact.
They already are saving billions. Elite is late to the game in Canada.
In what CC is that stated? That is not what he stated in the most recent cc.
The latest guidance is that the company will do all it can operationally and then perform a reverse split to get on the NASDAQ. It says nothing about doing it at $2.
Just stating my commentary after relistening to the CC. Even Nasrat himself stated the reality of CFO's comments were depressing albeit on a different subject.
I interpret the cc to have a lack of enthusiasm and confidence in near-term results.
Nasrat is also hoping to possibly hear from FDA later this year about Perc & NORCO. Not much confidence that they will hear soon.
Perhaps I am reading between the lines more than I should, but that was my latest reaction.
Don't forget the reverse split will help. Nasrat further alluded to it to get to NASDAQ on the recent call. Pipeline isn't nearly that strong to get us there without it.
I just re-listened to call this morning. I am expecting crap news for SequestOx study. Lots of "ifs" used during Nasrat's dialogue. Lack of conviction.
It was close to a 10-bagger if you shorted at 0.97.
Last Nasrat said on the deal is that they wouldn't budge on a deal until the BE was proven. Hmmmm...
Is that the reason why Puracap hasn't signed a SequestOx partnership the was due months and months ago?
I beg to differ. I am sure there will be many other deals akin to Trimipramine to be done.
That is like saying Nasrat will stop the self-dealing. Extremely unlikely. Especially with all signs leading to further ADT requirements. Percocet may not be approved for several more months, if at all this year.
Stock price is reacting as if the rug is going to be pulled out from under Elite again. Wouldn't be surprised in the slightest.
Was taken out pretty quickly.
Some have consistently held and many often trade. It is a fact. It is a reminder we all need to do our own DD and make judgments for our own portfolio. Just as Nasrat is protected with Safe Harbor language in future statements the same goes for this message board - tread with caution.
"There is no evidence that OXAYDO has reduced abuse liability compared to immediate-release oxycodone."
EGLT news hitting the wire. Here is an awesome snippet - "The oxycodone in Oxaydo may cause spasm of the sphincter..."
I love how Nasrat speaks about the total sales of each market. Similar to the equivalent in speaking of the Oxy market for our product with Epic. How is that one doing?
Unless the contract specifically states the J shares are unaffected. I have seen this clause with other companies, but do not think I saw it with Elite.
If I remember right the buyout means the J shares automatically get converted.
Stock - SequestOx results in July CAN give huge boost of confidence to company until we hear more on Perc & Norco, which I think will be longer than most would like, but that is just my opinion.
I am still pissed at the Tripramine deal. Yesterday's call didn't change that. Not a good use of resources when we are not cash flow positive and dilute further for deals like this.
And if it is approved who will do the sales & marketing? Doesn't seem like Nasrat is anticipating approval any time soon.
I believe this is the hard shell tech that caught shareholders by surprise. This Oxy product is not our usual dual-bear tech. Will be interesting to see actual data on this one to see comparative results.
It may do as well as Epic's Oxy product in which we share in the profits. Must be a 10-year ramp up process.
July could be a watershed moment for the company regarding SequestOx. This are the insights that we have all been on edge about anticipating directional guidance.
Nasrat's tone completely changed when talking about SequestOx. Very subdued and completely different from prior calls.
That was hilarious. Was about the cash dividend payment situation.
FDA is questioning worth of ADT's in Gottlieb's most recent statement. FDA is not going to do anything until proof is in the pudding and that will be very difficult to prove. We can be sure that nothing will happen anytime soon as those post-market studies will take years.
Easy zero. Keep dreaming though. There will be no such regulation.
Yes, but this would be years away. FDA approval gives a little confidence to the drug in an equivalent complex submission process.
Dr Jean Pfizer. That is hilarious! Does this count as having Pfizer as a partner?! Lol
I was assuming he meant the quarter starting in July ending in September & Sungen filing subsequent quarter. Sometimes he talks fiscal calendar & others the normal calendar. Hard to keep straight.
Likely excuse. What happens when sales slow? Inventory is elevated.
Sure. Clearly has nothing to do with the declining sales.